Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history

» Details

Guru Trades

Q2 2015

IBB Guru Trades in Q2 2015

George Soros 2,400 sh (New)
John Keeley 905 sh (unchged)
» More
Q3 2015

IBB Guru Trades in Q3 2015

George Soros Sold Out
John Keeley Sold Out
» More
Q4 2015

IBB Guru Trades in Q4 2015

Louis Moore Bacon 36,421 sh (New)
Steven Cohen 5,000 sh (New)
» More
Q1 2016

IBB Guru Trades in Q1 2016

George Soros 67,600 sh (New)
Steven Cohen Sold Out
Louis Moore Bacon Sold Out
» More

Ratios

vs
industry
vs
history
P/E(ttm) 20.67
IBB's P/E(ttm) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IBB: 20.67 )
Ranked among companies with meaningful P/E(ttm) only.
IBB' s P/E(ttm) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 20.67
Current: 20.67
0
20.67
PE(NRI) 20.67
IBB's PE(NRI) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IBB: 20.67 )
Ranked among companies with meaningful PE(NRI) only.
IBB' s PE(NRI) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 20.67
Current: 20.67
0
20.67
P/B 4.76
IBB's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IBB: 4.76 )
Ranked among companies with meaningful P/B only.
IBB' s P/B Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 4.76
Current: 4.76
0
4.76

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.09
IBB's Dividend Yield is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IBB: 0.09 )
Ranked among companies with meaningful Dividend Yield only.
IBB' s Dividend Yield Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0.09
Current: 0.09
0
0.09
Yield on cost (5-Year) 0.09
IBB's Yield on cost (5-Year) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. IBB: 0.09 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
IBB' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0.09
Current: 0.09
0
0.09

More Statistics

Short Percentage of Float0.00%
52-Week Range $244.04 - 397.96
Shares Outstanding (Mil)24,950,000.00
» More Articles for IBB

Headlines

Articles On GuruFocus.com
Market Indexes Lower as Market Considers Outlook May 23 2016 
Bruce Berkowitz Comments on DNOW May 23 2016 
Value Partners Group: Latest views on China Market May 23 2016 
GuruFocus Low P/S Strategies Outperformed By 7% Year-to-Date May 23 2016 
Baron Funds Comments on Bristol-Myers Squibb May 23 2016 
Baron Funds Comments on Illumina Inc. May 23 2016 
Baron Funds Comments on Regeneron Pharmaceuticals May 23 2016 
Baron Funds Comments on Alexion Pharmaceuticals May 23 2016 
Baron Funds Comments on Alexion Pharmaceuticals May 23 2016 
NeuroMetrix Officer Acquires 12,000 Shares May 23 2016 

More From Other Websites
Rlypsa Stock Pops on New Data and a Huge Risk May 23 2016
Stocks End Week On High Note; Chips, Biotechs Power Nasdaq May 20 2016
IBB Mid-Cap News: Pfizer Acquired Anacor for $5.2 Billion May 18 2016
Nasdaq dips into correction May 17 2016
Busting Another Election Year ETF Myth May 17 2016
Agilent Technologies Topped the Large Caps Last Week May 17 2016
Stock market bulls want to see breakouts here, quickly! May 17 2016
What Lies Ahead for Biotech ETFs? May 13 2016
Fear trades: Copper, biotech & shorting tech May 13 2016
Nasdaq, S&P dragged lower by Apple; Dow industrials end in the green May 12 2016
Analyzing Medivation’s Growth Opportunity with Xtandi May 12 2016
Biotech, China, Japan ETFs among 2016 Laggards: ETF.com May 11 2016
Wednesday links: a lack of confidence May 11 2016
Actinium Pharmaceuticals Remains Significantly Undervalued May 10 2016
The small cap squeeze: When more money chases fewer companies May 10 2016
S&P, Nasdaq eke out gains as health-care stocks rise; Dow sunk by oil slump May 09 2016
Charts See Possible Value in Apple, Facebook May 08 2016
Startling Disclosure in Relypsa's Filings Reveal a Possible Sanofi Takeover May 08 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK